title: Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke.
abstract: Antiplatelet effects of angiotensin II receptor blocker have been suggested, but satisfactory results in clinical settings are lacking. We investigated spontaneous platelet aggregation (SPA) and CD62P levels in patients with hypertension and chronic-stage ischemic stroke. The study comprised 35 patients assigned to losartan (50 mg/day) or telmisartan (40 mg/day) for 4 weeks randomly. SPA was evaluated using laser-scattered light aggregometry and CD62P levels using whole blood flow cytometry before and after treatment. SPA was not significantly reduced after losartan or telmisartan treatment. CD62P was significantly reduced after losartan treatment (P = .016), but no significant differences were noted with telmisartan. These findings suggest that standard doses of losartan display antiplatelet effect as measured by CD62P levels.
authors.affiliation: Department of Neurology, St Marianna University School of Medicine, Kawasaki, Japan. ky0723@marianna-u.ac.jp
authors.forename: Koji
authors.initials: K
authors.lastname: Yamada
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Hirayama
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Hasegawa
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects* / Q000276:immunology; D002545:Brain Ischemia / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D002908:Chronic Disease; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D019808:Losartan / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010979:Platelet Function Tests; D020521:Stroke / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000077333:Telmisartan; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D015415:Biomarkers; D019007:P-Selectin; D010975:Platelet Aggregation Inhibitors; D019808:Losartan; D000077333:Telmisartan